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In randomized controlled trials as well as in observational
studies, researchers are often interested in effects of treat-
ment or exposure in different subgroups, i.e. effect modi-
ﬁcation [1, 2]. There are several methods to assess effect
modiﬁcation and the debate on which method is best is still
ongoing [2–5]. In this article we focus on an invalid
method to assess effect modiﬁcation, which is often used in
articles in health sciences journals [6], namely concluding
that there is no effect modiﬁcation if the conﬁdence
intervals of the subgroups are overlapping [7–9].
When assessing effect modiﬁcation by looking at over-
lap of the 95% conﬁdence intervals in subgroups, a type 1
error probability of 0.05 is often mistakenly assumed. In
other words, if the conﬁdence intervals are overlapping, the
difference in effect estimates between the two subgroups is
judged to be statistically insigniﬁcant. By using mathe-
matical derivation, we calculated that the chance of ﬁnding
non-overlapping 95% conﬁdence intervals under the null
hypothesis is 0.0056 if the variance of both effect estimates
is equal and the effect estimates are independent (see
Supplemental material for derivation of this probability). If
the variance of the effect estimates is not equal, the chance
of ﬁnding non-overlapping 95% conﬁdence intervals can
be calculated by taking into account q, i.e. the ratio
between the standard deviations in the subgroups, r2/r1
(Supplementary material, formula (3)). Figure. 1 shows the
relation between q and the type 1 error probability if the
effect estimates are independent. If the effect estimates are
not independent, the correlation coefﬁcient between the
effect estimates can also be accounted for (Supplementary
material, formula (3)).
To arrive at a type 1 error probability of 0.05, 83.4%
conﬁdence intervals should be calculated around the effect
estimates in subgroups if the variance is equal and the effect
estimates are independent (see Supplementary material for
derivation of this percentage). If the variance is not equal, q
should be taken into account (Supplementary material,
formula (11)). Figure. 2 shows the relation between q and
the level of the conﬁdence interval. If the effect estimates
are not independent, the correlation coefﬁcient should be
taken into account (Supplementary material, formula (11)).
Adapting the level of the conﬁdence interval can be espe-
cially useful for graphical presentations, for example in
meta-analyses [10]. However, it is necessary to explicitly
and clearly state which percentage conﬁdence interval is
calculated and its meaning should be thoroughly explained
to the reader. Many readers will still interpret this ‘new’
conﬁdence interval as if it were a 95% conﬁdence interval,
because this percentage is so commonly used. To prevent
such confusion, other methods to assess effect modiﬁcation
could be used, such as calculating a 95% conﬁdence interval
around the difference in effect estimates [8].
The assumption used in the formulas presented in the
appendices is that the effect estimators in the subgroups are
normally distributed. Assuming that epidemiologic effect
measures, such as the odds ratio, risk ratio, hazard ratio and
risk difference, follow a normal distribution, the methods
presented can also be used for these epidemiologic mea-
sures. Note that the assumption for normality is generally
unreasonable in small samples, but a satisfactory approxi-
mation in large samples.
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As an example, imagine a large randomized controlled trial
that investigates the effect of some intervention on mor-
tality and that includes 10,000 men and 5,000 women.
Besides the main effect of treatment, the researchers are
interested in assessing whether the treatment effect is dif-
ferent for men and women. Suppose that the risk ratio in
men is 0.67 (95% CI: 0.59-0.75) and in women is 0.83
(95% CI: 0.71-0.98). The conﬁdence intervals are partly
overlapping, which the researchers may wrongly interpret
as no effect modiﬁcation by sex. Filling in formula (3)
(Supplementary material) results in a probability of non-
overlapping 95% conﬁdence intervals under the null
hypothesis of 0.006. A conﬁdence level of 83.8% could
have been calculated to arrive at a type 1 error probability
of 0.05, resulting in a conﬁdence interval of 0.61–0.73 for
men and 0.74–0.93 for women. Now, the conﬁdence
intervals do not overlap, so the p-value is at least smaller
than 0.05, indicating statistically signiﬁcant effect modiﬁ-
cation. Calculating the difference in risk ratios with a 95%
conﬁdence interval results in a ratio of risk ratios of 0.80
with a 95% conﬁdence interval of 0.66-0.98, corresponding
to a p-value of 0.028. This conﬁrms our earlier observation
of statistically signiﬁcant effect modiﬁcation.
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Fig. 2 Relation between q, which is the ratio of r2 and r1, and the
percentage conﬁdence intervals to be calculated to arrive at a type 1
error probability of 0.05
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Fig. 1 Relation between q, which is the ratio of r2 and r1, and the
probability of non-overlapping conﬁdence intervals under the null
hypothesis (type 1 error)
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